Abstract: This invention relates in one aspect to non-natural desamino alkyl amino acid compounds, methods of making these compounds, and peptides containing these compounds. In one embodiment, the peptide is neurotensin (8-13) in which the N-terminus is an alpha-desamino, alpha-methyl-N,N-dimethyl-homolysine residue of the invention.
Type:
Grant
Filed:
March 4, 2013
Date of Patent:
June 7, 2016
Assignee:
MUSC Foundation for Research Development
Abstract: The present invention provides methods for guiding preservation of neurons or nerves during surgery by administering a fluorescently-labeled peptide that associates with (e.g., specifically binds to) the neurons or nerves. The invention further provides targeting molecules of fluorescently-labeled peptides or aptamers that associate with (e.g., specifically bind to) neurons or nerves and for compositions thereof.
Abstract: The present invention provides a process for preparing a compound of Formula 5b, as well as intermediates thereof, and novel classes of compounds useful in process for preparing these and similar compounds.
Type:
Grant
Filed:
December 10, 2012
Date of Patent:
May 31, 2016
Assignee:
PFIZER INC.
Inventors:
Javier Magano, Mark Thomas Maloney, Olivier J. Marcq, Durgesh Vasant Nadkarni, Mark John Pozzo, John Joseph Teixeira, Jr.
Abstract: The present invention relates to the newly identified timerization initiating and stagger determining capacity of the NC2 domain of collagen IX. The invention further relates to a hexavalent molecular building block wherein the linkage of additional moieties to the amino and carboxyl terminals of monomers comprising the NC2 domain of collagen IX promotes the directed association of those moieties via the trimerization initiating and stagger determining capacity of the NC2 domain of collagen IX.
Abstract: The present invention provides new uroguanylin derivatives that are useful for the treatment of gastrointestinal disorders. The present invention also provides compositions and methods of treating gastrointestinal disorders and pharmaceutical compositions for accomplishing the same. In some embodiments, these pharmaceutical compositions include oral dosage forms.
Type:
Grant
Filed:
May 11, 2012
Date of Patent:
April 5, 2016
Assignee:
Ironwood Pharmaceuticals, Inc.
Inventors:
Mark G. Currie, Daniel P. Zimmer, Marco Kessler
Abstract: The invention relates to a hemostatic composition in powder form comprising collagen of the fibrillar type comprising a content of fibrous collagen and/or fibrillar collagen of at least 70% by weight relative to the total weight of the collagen, and at least one monosaccharide, and optionally, at least one compound selected from coagulation factors and glycosaminoglycans. The invention further relates to a method for preparing such composition, and to a unit comprising such composition and a spraying device.
Type:
Grant
Filed:
April 26, 2012
Date of Patent:
March 15, 2016
Assignee:
BIOM'UP
Inventors:
Christian Gagnieu, Patricia Forest, Sylvain Picot
Abstract: The invention provides polymers comprising Formula I: wherein monomer is a repeating unit comprising 2, 3, 4, 5, 6 or 7 carbon atoms and the monomers are linked together through amide or ester bonds; n is about 6 to about 1000; and Linker is an optionally substituted carbon chain that is optionally interrupted by moieties such as oxygen, nitrogen, sulfur, phosphorus, or silicon. Charge is a moiety having a positive or negative charge on a heteroatom, such as nitrogen, oxygen, phosphorus, or sulfur; where the Linker separates the monomer and the Charge by at least six linear atoms. The invention also provides methods of preparing the polymers and the copolymers and methods of using the polymers and copolymers, for example, as drug delivery systems, as membrane penetrating peptides, and as therapeutic agents.
Type:
Grant
Filed:
November 30, 2011
Date of Patent:
January 26, 2016
Assignee:
The Board of Trustees of the University of Illinois
Abstract: A peptide including 8 animo acids having a sequence of cNGEGQQc, where c represents d-cysteine (Cys), N represents L-Asparagine (Asn), G represents L-Glycine (Gly), E represents L-Glutamic acid (Glu), and Q represents L-Glutamine (Gln).
Type:
Grant
Filed:
October 27, 2014
Date of Patent:
January 12, 2016
Assignee:
GUANGZHOU PEPTIDE MEDICAL TECHNOLOGY CO., LTD.
Inventors:
Linlang Guo, Guiping Li, Zhenzhu Chen, Yajie Liu
Abstract: The present invention relates to antimicrobial peptides, to their use as antimicrobial agents and to their use in the treatment of (infectious) diseases, in particular infectious diseases caused by Gram-positive bacteria, Gram-negative bacteria, yeast or fungi. The present invention further relates to pharmaceutical compositions and kits comprising the antimicrobial peptides and to a method of lysing bacterial, yeast or fungal cells. The antimicrobial peptides consist of one of the following general formula: Wherein X is a hydrophobic amino acid, Y is a cationic amino acid, Z is an amino acid having a free thiol or thioether group, n is 2-4 and m is 0 or 1.
Type:
Grant
Filed:
October 31, 2011
Date of Patent:
January 12, 2016
Assignee:
Agency for Science, Technology and Research
Inventors:
Yi-Yan Yang, Nikken Wiradharma, Charlotte A. E. Hauser
Abstract: This invention provides WT1 peptides and methods of treating, reducing the incidence of, and inducing immune responses against a WT1-expressing cancer, comprising same.
Type:
Grant
Filed:
September 16, 2013
Date of Patent:
January 12, 2016
Assignee:
SLOAN KETTERING INSTITUTE FOR CANCER RESEARCH
Inventors:
David A. Scheinberg, Javier Pinilla-Ibarz, Rena May
Abstract: The present disclosure generally relates to collagen, and more particularly compositions and methods related to collagen-mimetic peptides. More specifically, the present disclosure provides a collagen-mimetic peptide and peptide systems comprising the amino acid sequence (Pro-Lys-Gly)4(Pro-Hyp-Gly)4(Asp-Hyp-Gly)4.
Type:
Grant
Filed:
February 10, 2014
Date of Patent:
January 5, 2016
Assignee:
WILLIAM MARSH RICE UNIVERSITY
Inventors:
Jeffrey D. Hartgerink, Lesley R. O'Leary
Abstract: The present invention relates to the use of an antisecretory factor (AF) protein, peptide, derivative, homologue, and/or fragment thereof, having equivalent functional activity, and/or a pharmaceutically active salt thereof, for optimizing delivery and cellular uptake of a pharmaceutical substance and/or formulation, or a gene delivery. Typically, said pharmaceutical substance and/or formulation comprises an anticancer drug, radiation therapy, an antibiotic substance, an antiviral substance or a drug targeting posttraumatic injury, neurodegeneration, a parasite, or an inflammatory condition.
Type:
Grant
Filed:
February 11, 2010
Date of Patent:
December 29, 2015
Assignee:
LANTMANNEN AS-FAKTOR AB
Inventors:
Eva Jennische, Stefan Lange, Hans-Arne Hansson
Abstract: The present invention relates to a method of improving the resistance of a peptide or peptidomimetic to degradation by trypsin which comprises incorporating into said peptide or peptidomimetic a C-terminal capping group of formula (I): X—Y—Z (I) wherein X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from —Ra—Rb—, —Ra—Rb—Rb,- and —Rb—Rb—Ra— wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb, may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z. moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z.
Type:
Grant
Filed:
December 22, 2008
Date of Patent:
December 15, 2015
Assignee:
Lytix Biopharma AS
Inventors:
Wenche Stensen, Oystein Rekdal, John Sigurd Svendsen
Abstract: The present disclosure relates to methods and compositions comprising naturally occurring light absorbing molecules for preventing damages from light exposure. Specific embodiments of this disclosure include fluorescent proteins from Brachiostoma lanceolatum.
Type:
Grant
Filed:
August 9, 2011
Date of Patent:
December 8, 2015
Assignee:
Allele Biotechnology & Pharmaceuticals, Inc.
Abstract: The invention provides methods of preparing macrocycles including macrocycle stabilized peptides (MSPs). Macrocycles and MSPs are prepared according to nucleophilic capture of an iminoquinomethide type intermediate generated from a suitably substituted 2-amino-thiazol-5-yl carbinol. The preferred nucleophile may be selected from an electron rich aromatic moiety in the case of macrocycles and, in the case of MSPs, at least one amino acid comprises an electron rich aromatic moiety. In addition, the concept can be extended to other related 5-membered heterocyclic systems in place of the thiazole, such as imidazole or oxazole. The conditions for the generation of the corresponding iminoquinomethide type intermediates may be similar or different than the conditions used for the 2-amino-thiazol-5-yl carbinol.
Type:
Grant
Filed:
October 13, 2011
Date of Patent:
October 27, 2015
Assignee:
Bristol-Myers Squibb Company
Inventors:
Mark G. Saulnier, Dolatrai M. Vyas, David R. Langley, David B. Frennesson
Abstract: A fusion protein comprising at least one Type 1 Ribosome Inactivating Protein, polypeptide B; and at least one polypeptide A capable of viral entry inhibition; and/or at least one Cationic AntiMicrobial Peptide, polypeptide C.
Type:
Grant
Filed:
January 9, 2012
Date of Patent:
October 13, 2015
Assignee:
VALIANT BIOPHARMA SDN BHD
Inventors:
Muhammad Sagaf Abu Bakar, Ag., Eng Huan Ung
Abstract: Methods of treatment or prophylaxis of bacterial vaginosis, prevention of recurrence of bacterial vaginosis and alleviation or prevention of symptoms or diagnostic criteria of bacterial vaginosis are provided. The methods include administration of an effective amount of a macromolecule comprising a polylysine, polyamidoamine, poly(etherhydroxyamine) or poly(propyleneimine) dendrimer and one or more sulfonic acid containing moieties attached thereto.
Type:
Grant
Filed:
May 16, 2012
Date of Patent:
October 13, 2015
Assignee:
STARPHARMA PTY LIMITED
Inventors:
Jeremy Robert Arthur Paull, Jacinth Kincaid Fairley, Clare Frances Price, Gareth Rhys Lewis
Abstract: The present invention is directed to a hemostatic or tissue sealing material having (a) a peptide having a sequence SEQ ID NO: 1 or an amino acid analog sequence thereof, and (b) a scaffold for said peptide or amino acid analog sequence. The scaffold is preferably hemostatic, such as a natural or genetically engineered absorbable polymer, a synthetic absorbable polymer, or combinations thereof. The natural or genetically engineered absorbable polymers can be selected from the group consisting of a protein, a polysaccharide, or combinations thereof.
Abstract: Neurturin polypeptides which possess reduced heparin and heparan sulfate binding affinity but retain neurotrophic activity, nucleic acids which encode the neurturin variants and vectors and host cells which express the enhanced neurturin polypeptides. Use of the enhanced neurturin polypeptides, nucleic acids and host cells in the treatment or prevention of disease.
Type:
Grant
Filed:
March 18, 2013
Date of Patent:
September 8, 2015
Assignee:
NTF Therapeutics, Inc.
Inventors:
Pia Runeberg-Roos, Maxim M. Bespalov, Richard Penn, Mart Saarma